Aristolochic acid in the etiology of renal cell carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 12, 2016, Pages 1600-1608

  Hoang, Margaret L ^a   Chen, Chung Hsin ^b   Chen, Pau Chung ^c   Roberts, Nicholas J ^a   Dickman, Kathleen G ^d   Yun, Byeong Hwa ^e   Turesky, Robert J ^e   Pu, Yeong Shiau ^b   Vogelstein, Bert ^a   Papadopoulos, Nickolas ^a   Grollman, Arthur P ^d   Kinzler, Kenneth W ^a   Rosenquist, Thomas A ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOLACTAM; DEOXYADENOSINE; DEOXYGUANOSINE; GENOMIC DNA; PBRM1 PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; ARISTOLOCHIC ACID I; CARCINOGEN; DNA; MUTAGENIC AGENT;

ALLELE; ARTICLE; BINDING SITE; CANCER INCIDENCE; CANCER RISK; CHROMOSOME 3P; CHROMOSOME LOSS; CONTROLLED STUDY; DNA ADDUCT; DNA ISOLATION; DNA REPAIR; EXOME; EXON; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; KIDNEY CORTEX; MASS SPECTROMETRY; NUCLEIC ACID BASE SUBSTITUTION; PATHOGENESIS; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SANGER SEQUENCING; SOMATIC MUTATION; TAIWAN; WHOLE EXOME SEQUENCING; ADULT; AGED; ANALYSIS; CASE CONTROL STUDY; CHEMICALLY INDUCED; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; FEMALE; GENETICS; KIDNEY; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; RENAL CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARISTOLOCHIC ACIDS; CARCINOGENS; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; DNA; DNA ADDUCTS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTAGENS; MUTATION; TAIWAN;

EID: 85006277721     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0219     Document Type: Article

References (33)

1. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991;88:10124-8.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
4. Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, et al. Mutational signature of aristolochic acid exposure as revealed by wholeexome sequencing. Sci Transl Med 2013;5:197ra02.
5. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, et al. Genomewide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 2013;5:197ra01.
6. Kumar V, Poonam, Prasad AK, Parmar VS. Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat Prod Rep 2003;20:565-83.
7. Grollman AP, Scarborough J, Jelakovic B. Aristolochic acid nephropathy: an environmental and iatrogenic disease. In: Fishbein J, editor. Advances in molecular toxicology. Amsterdam, the Netherlands: Elsevier; 2009. p. 211-22.
8. Schmeiser HH, Schoepe KB, Wiessler M. DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 1988;9:297-303.
9. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 2007;104:12129-34.
10. Jelakovic B, Karanovic S, Vukovic-Lela I, Miller F, Edwards KL, Nikolic J, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012;81:559-67.
11. Schmeiser HH, Nortier JL, Singh R, Gamboa da Costa G, Sennesael J, Cassuto-Viguier E, et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer 2014;135: 502-7.
12. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012;109:8241-6.
13. Hsieh SC, Lin IH, Tseng WL, Lee CH, Wang JD. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin Med 2008;3:13.
14. Fernando RC, Schmeiser HH, Scherf HR, Wiessler M. Formation and persistence of specific purine DNA adducts by 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I. IARC Sci Publ 1993;124:167-71.
15. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP. Selective toxicity of aristolochic acids I and II. Drug Metab Dispos 2007;35:1217-22.
16. Poon SL, Huang MN, Choo Y, McPherson JR, Yu W, Heng HL, et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med 2015;7:38.
17. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012;44:1117-21.
18. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014;46:1267-73.
19. Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun 2014;5:5696.
20. Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012;44:17-9.
21. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzalez-Porta M, Wozniak MB, et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun 2014;5:5135.
22. Jelakovic B, Castells X, Tomic K, Ardin M, Karanovic S, Zavadil J. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int JCancer 2015;136:2967-72.
23. Turesky RJ, Yun BH, Brennan P, Mates D, Jinga V, Harnden P, et al. Aristolochic acid exposure in Romania and implications for renal cell carcinoma. Br J Cancer 2016;114:76-80.
24. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based casecontrol study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010;102:179-86.
25. Goodenough AK, Schut HA, Turesky RJ. Novel LC-ESI/MS/MS(n) method for the characterization and quantification of 2'-deoxyguanosine adducts of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5- b]pyridine by 2-D linear quadrupole ion trap mass spectrometry. Chem Res Toxicol 2007;20:263-76.
26. Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, et al. Biomonitoring of aristolactam-DNA adducts in human tissues using ultraperformance liquid chromatography/ion-trap mass spectrometry. Chem Res Toxicol 2012;25:1119-31.
27. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
28. Carroll PR, Murty VV, Reuter V, Jhanwar S, Fair WR, Whitmore WF, et al. Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet 1987;26:253-9.
29. Nassar D, Latil M, Boeckx B, Lambrechts D, Blanpain C. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat Med 2015;21:946-54.
30. Sidorenko VS, Yeo JE, Bonala RR, Johnson F, Scharer OD, Grollman AP. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res 2012;40:2494-505.
31. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008;74:158-69.
32. Yang L, Su T, Li XM, Wang X, Cai SQ, Meng LQ, et al. Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol Dial Transplant 2012;27:292-8.
33. Gluhovschi G, Margineanu F, Kaycsa A, Velciov S, Gluhovschi C, Bob F, et al. Therapeutic remedies based on Aristolochia clematitis in the main foci of Balkan endemic nephropathy in Romania. Nephron Clin Pract 2010;116:c36-46.